Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

Rabbit Monoclonal Antibodies Now Available for Use in Cancer-Related Research

By BiotechDaily International staff writers
Posted on 08 Aug 2011
Cancer researchers now have access to 23 novel, cancer-related rabbit monoclonal antibodies that have been released to the commercial market.

The antibodies are the fruit of cooperation between the [US] National Cancer Institute (Bethesda, MD, USA) and the biotechnology company Epitomics, Inc. (Burlingame, CA, USA). Epitomics has developed a unique and proprietary method for making monoclonal antibodies from rabbits rather than the conventional method of starting with mice.

The basic principal for making the antibody is the same as for mouse monoclonal antibodies. Proprietary rabbit fusion-partner cells fuse to rabbit B-cells to create rabbit hybridoma cells. Hybridomas are then screened to select for clones with specific and sensitive antigen recognition, and the antibodies are characterized using a variety of methods. The rabbit immune system generates antibody diversity and optimizes affinity by mechanisms that are more efficient than those of mice and other rodents. This increases the possibility of obtaining a functional antibody that will work in a variety of applications.

This technology - combined with the expertise of researchers at the National Cancer Institute – has produced a line of 23 rabbit monoclonal antibodies that should be of use to cancer investigators. The antibodies are available for purchase in the United States directly through Epitomics and around the world through Epitomics’ international distributors. The collaborators plan to develop another 20 antibodies for commercial release over the next two years.

“We are very excited to see the progress we have made in developing several key antibodies with National Cancer Institute investigators and look forward to continuing working with them to develop high quality rabbit monoclonal antibodies,” said Dr. Guo-Liang Yu, CEO of Epitomics, Inc.

Related Links:

National Cancer Institute
Epitomics, Inc.



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: S-649266 has more robust antibacterial activity than established antibiotics against multidrug-resistant bacteria (Photo courtesy of Shionogi).

Novel Antibiotic Shows Potential for Broad Range of Infections

The emergence of bacterial resistance to known antibacterial agents is becoming a major challenge in treating the infection caused by multi drug resistant (MDR) bacteria. In order to treat bacterial... Read more

Lab Technologies

view channel
Image: Leica Microsystems launches the inverted research microscope platform Leica DMi8 (Photo courtesy of Leica Microsystems).

New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.... Read more

Business

view channel

Collaboration of Mayo Clinic and IBM Cognitive Computer Devised to Improve Clinical Trial Research

The Mayo Clinic (Rochester, MN, USA) and IBM (Armonk, NY, USA) recently announced plans to pilot Watson, the IBM cognitive computer, to match patients more rapidly with suitable clinical trials. A proof-of-concept phase is currently ongoing, with the intent to introduce it into clinical use in early 2015.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.